Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny particles in knee arteries could offer new pain relief for arthritis

NCT ID NCT07537153

Symptom relief Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 15, 2026 · Updated 4 times

Summary

This study tests a procedure called Genicular Artery Embolization for people with mild-to-moderate knee osteoarthritis. Doctors inject tiny particles into arteries that supply the knee lining to reduce blood flow and hopefully ease pain. Fifteen participants will be followed for three years to check safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Embosphere Microspheres (tiny particles injected into knee arteries)
What this could lead to
If it works, this could offer a new, minimally invasive option to ease knee pain and improve function for people with mild-to-moderate osteoarthritis.
What could go wrong
This is a very small, early-phase study with only 15 people, so results may not apply widely. Risks include pain, skin changes, or accidental blockage of other blood vessels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Apr 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 40-80 years * Mild-to-moderate knee OA as determined by radiographs demonstrating Kellgren- Lawrence grade 2-3 * Self-reported pain of at least 5/10 VAS questionnaire * Failure of conservative therapy, such as pain medications, for at least 3 months * Patient must understand and sign the informed consent * Patient can comply with the proposed follow-up schedule * Patient can follow the post-operative management Exclusion Criteria: * History of rheumatoid arthritis * Renal insufficiency precluding angiography (GFR \< 50 mL/min) * Irreversible coagulopathy * Previous knee arthroplasty on the intended knee * Existing knee joint infection * Kellgren-Lawrence grade 1 or 4 * Severe atherosclerosis as manifest by claudication and/or diminished peripheral pulses * Life expectancy \< 6 months * Infectious arthritis * Allergy to iodinated contrast resulting in anaphylaxis * Pregnant or interested in becoming pregnant three months from the date of the GAE procedure * Involved in litigation or worker's compensation claims

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Knee osteoarthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoarthritis osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Knee osteoarthritis Osteoarthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.